Pesquisar um ensaio clínico
Outras opções de pesquisa
238 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Ensaio concluído = 
; Financiado por um membro do IRDiRC = 
; Estudo envolvendo membros das ERN em pelo menos dois Estados-Membros = 
Ensaio (s) clínico (s) nacional (is)
ALEMANHA
Bayern
MÜNCHEN
PHITT: Paediatric Hepatic International Tumour Trial - DE
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital
Zentrum für Pädiatrische Hämatologie und Onkologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
PHITT: Paediatric Hepatic International Tumour Trial (Phase 3) - AT
Institution: Information not provided - AT
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
LOUVAIN-LA-NEUVE
PHITT: Paediatric Hepatic International Tumour Trial. -BE
Université Catholique de Louvain - UCL
Université catholique de Louvain
COREIA DO SUL
KOREA, REPUBLIC OF
ADDRESS: NOT PROVIDED
PHITT: Paediatric Hepatic International Tumour Trial. -IE
Institution: Information not provided - KR
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
PHITT: Paediatric Hepatic International Tumour Trial -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A multi-center, open-label, non-randomized, phase I dose escalation study of regorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard therapy -ES
Institution: Information not provided - ES
FRANCA
BRETAGNE
RENNES
PHITT: Paediatric Hepatic International Tumour Trial. -FR
CHU de Rennes - Hôpital Pontchaillou
CHU Rennes
ISRAEL
ISRAEL
ADDRESS: NOT PROVIDED - IL
PHITT: Paediatric Hepatic International Tumour Trial. -IL
Institution: Information not provided - IL
NORUEGA
Østlandet
ADDRESS: NOT PROVIDED - NO
PHITT: Paediatric Hepatic International Tumour Trial. -NO
Institution: Information not provided - NO
PAISES BAIXOS
Utrecht
ADDRESS: NOT PROVIDED - NL
PHITT: Paediatric Hepatic International Tumour Trial. -NL
Institution: Information not provided - NL
POLONIA
Gdansk
GDANSK
PHITT: Paediatric Hepatic International Tumour Trial. -PL
Medical University of Gdansk
REINO UNIDO
Dorset
BOURNEMOUTH
SIOPEL 4: Intensified Pre-Operative Chemotherapy And Radical Surgery For High Risk Hepatoblastoma (Phase II/III)
Royal Bournemouth Hospital
Department of Haematology
REINO UNIDO
Dorset
BOURNEMOUTH
SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma (Phase III) - IE
Royal Bournemouth Hospital
Department of Haematology
REINO UNIDO
Greater London
ADDRESS: NOT PROVIDED - GB
PHITT: Paediatric Hepatic International Tumour Trial. -GB
Institution: Information not provided - GB
REPUBLICA CHECA
Capital City Prague
ADDRESS: NOT PROVIDED - CZ
PHITT: Paediatric Hepatic International Tumour Trial. -CZ
Institution: Information not provided - CZ
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
PHITT: Paediatric Hepatic International Tumour Trial. -CH
Institution: Information not provided - CH
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
DAREON(TM)-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas - DE
Institution: Information not provided - DE
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
DAREON(TM)-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas - ES
Institution: Information not provided - ES
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Institution: Information not provided - US
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
DAREON(TM)-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas - FR
Institution: Information not provided - FR
PAISES BAIXOS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
REINO UNIDO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
DAREON(TM)-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas - GB
Institution: Information not provided - UK
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
PHP-ICC-203: A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) in Patients with IntraHepatic Cholangiocarcinoma
Institution: Information not provided - DE
ALEMANHA
Hessen
FRANKFURT AM MAIN
ADJUBIL: A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer
Krankenhaus Nordwest GmbH
Institut für Klinische Krebsforschung IKF GmbH
ALEMANHA
Niedersachsen
HANNOVER
Phase II Study of Immunotherapy With Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, Both Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Medizinische Hochschule Hannover
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
ALEMANHA
Niedersachsen
HANNOVER
CheckMate 74W: A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC) - DE
Medizinische Hochschule Hannover
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
ALEMANHA
Nordrhein-Westfalen
DÜSSELDORF
ProvIDHe: An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Universitätsklinikum Düsseldorf
Klinik für Gastroenterologie, Hepatologie und Infektiologie
ALEMANHA
Rheinland-Pfalz
MAINZ
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma -DE
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
I. Medizinische Klinik und Poliklinik
ALEMANHA
Sachsen
LEIPZIG
CheckMate 74W: A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC) - DE
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
ACTICCA-1: Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Open-label First Line, Single-arm Phase II Study of CisGem Combined With Pembrolizumab in Patients With Advanced or Metastatic Biliary Tract Cancer - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
FIGHT-302: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
FORTITUDE-301: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
CheckMate 459: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ANDERLECHT (BRUSSELS)
A Pilot Study of BMS-936558 With Stereotactic Ablative Radiation Therapy After Induction Chemotherapy in Cholangiocarcinoma - BE
Hôpital Universitaire de Bruxelles (H.U.B) - Site Institut Jules Bordet
Oncologie digestive
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie-Oncologie thoracique
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CheckMate 74W: A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC) - BE
Cliniques universitaires Saint-Luc - UCLouvain
Oncologie digestive
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
FIGHT-202: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - BE
Hôpital Universitaire de Bruxelles (H.U.B) - Site Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
REACHIN: Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (non resectable) and metastatic cholangiocarcinoma: a randomized double-blinded phase II trial - BE
Hôpital Universitaire de Bruxelles (H.U.B) - Site Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGICA
VLAAMS BRABANT
LEUVEN
A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations - BE
UZ Leuven - Campus Gasthuisberg
Digestieve oncologie/Digestive Oncology
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
FIGHT-302: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
HERIZON-BTC-01: A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-966: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
GEMINI-Hepatobiliary: A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer - ES
Institution: Information not provided - ES
ESPANHA
Madrid
MADRID
FIRST-308: A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma - ES
Hospital Universitario Fundación Jiménez Díaz
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase I Study of Single Agent SF1126, a Dual PI3 Kinase and Bromodomain Inhibitor, in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A-B7 Cirrhosis
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
TAS-102 in Treating Advanced Biliary Tract Cancers
Institution: Information not provided - US
FRANCA
AUVERGNE-RHONE-ALPES
SAINT-ÉTIENNE
AMEBICA : Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours
CHU de Saint-Étienne - Hôpital Bellevue
Service de Gastro-entérologie et Hépatologie - Cancérologie digestive
FRANCA
BRETAGNE
RENNES
An Open-label, Multicenter, Phase II Trial, to Evaluate the Efficacy of Intra-hepatic Administration of Yttrium 90-labelled Microspheres (Therasphere®, Nordion) in Association With Intravenous Chemotherapy With Gemcitabine and Cisplatin for the Treatment of Intra-hepatic Cholangiocarcinoma, First Line. (Phase II) - FR
CLCC Eugène Marquis
Département d'Oncologie Médicale
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (Phase III) - FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
HIPANIV: A Phase I Study Evaluating Safety and Efficacy of Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma -FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC) -FR
Institution: Information not provided - FR
FRANCA
OCCITANIE
MONTPELLIER
Neoadjuvant Atezolizumab and Adjuvant Atezolizumab + Bevacizumab in Combination With Percutaneous Radiofrequency Ablation of Small HCC: a Multicenter Randomized Phase II Trial
ICM - Institut régional du Cancer de Montpellier
Service d'oncologie médicale - Médecine B3
FRANCA
PROVENCE-ALPES-COTE D'AZUR
AVIGNON
FIRST-308: A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma -FR
Institut Sainte Catherine
Oncologie médicale
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma - IT
Institution: Information not provided - IT
ITALIA
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O.C. Oncoematologia, Trapianto Emopoietico e Terapie Cellulari
JAPAO
JAPAN
ADDRESS : NOT PROVIDED - JP
TOPAZ-1: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers - JP
Institution: Information not provided - JP
JAPAO
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma
Institution: Information not provided - JP
JAPAO
JAPAN
ADDRESS : NOT PROVIDED - JP
Nivolumab and Ipilimumab or Nivolumab or Placebo Plus TACE in Intermediate-stage Liver Cancer (CA20974W)
Institution: Information not provided - JP
JAPAO
JAPAN
YOKOHAMA
Randomized phase III trial of Sorafenib versus Lenvatinib as a second-line treatment after immune check point inhibitor for advanced hepatocellular carcinoma (JON2102-H (SUCCEED))
Kanagawa Cancer Center
REINO UNIDO
Avon
BRISTOL
TOPAZ-1: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers-GB
Bristol Royal Infirmary
University Hospitals Bristol NHS Foundation Trust HQ
REINO UNIDO
Glasgow
GLASGOW
A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations-GB
Beatson West of Scotland Cancer Centre
REINO UNIDO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
TOPAZ-1: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers-GB
Institution: Information not provided - UK
REINO UNIDO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) - GB
Institution: Information not provided - UK
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - GB
Institution: Information not provided - CH
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
CheckMate 74W: A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC) - CH
Institution: Information not provided - CH
ALEMANHA
Baden-Württemberg
TÜBINGEN
CheckMate 459: A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma - DE
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin I - Gastroenterologie, Hepatologie und Infektiologie
ALEMANHA
Bayern
MÜNCHEN
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation -DE-
Geschäftsstelle CCC München
CCC München - Comprehensive Cancer Center
ALEMANHA
Bayern
MÜNCHEN
DEMAND: A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable HCC patients
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik II
ALEMANHA
Bayern
WÜRZBURG
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation -DE-
Zentrum Innere Medizin (ZIM)
Medizinische Klinik und Poliklinik II
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma -DE-
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
ARTISTRY-2: A Phase 1/2 study of ALKS 4230 administered subcutaneously as monotherapy and in combination with Pembrolizumab in subjects with advanced solid tumors - DE
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
An Open-Label Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) after PD-1/PD-L1 Immune Checkpoint Inhibitors -DE
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma -DE
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
SIERRA: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma -DE
Institution: Information not provided - DE
ALEMANHA
Hessen
FRANKFURT AM MAIN
SOLARIS : A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refractory to atezolizumab and bevacizumab/ IO-based therapy
Krankenhaus Nordwest GmbH
Institut für Klinische Krebsforschung IKF GmbH
ALEMANHA
Niedersachsen
HANNOVER
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation -DE-
Medizinische Hochschule Hannover
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
ALEMANHA
Niedersachsen
HANNOVER
IMMUWIN: A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design
Medizinische Hochschule Hannover
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
ALEMANHA
Nordrhein-Westfalen
KÖLN
A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE-
Universitätsklinikum Köln
ALEMANHA
Sachsen
DRESDEN
CaPture: Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 inhibitors
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
ALEMANHA
Sachsen
LEIPZIG
CaPture: Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 inhibitors
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
COSMIC-312: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
EMERALD-2: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
CheckMate 9DW: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
CheckMate 74W: A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
MASTERKEY-318: A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab [...] in Phase 2 - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
The ABC-HCC Trial: A Phase IIIb, Randomized, Multicenter, Open-label Trial of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
OUTREACH2: An Open Label, Randomised Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination With Sorafenib or Sorafenib Alone in TKI naïve Participants With Previously Treated Advanced Hepatocellular Carcinoma (HCC) and Hepatitis B or Hepatitis C Virus - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
HBIG-Pilot: Impact of Hepatitis B immunoglobulins in patients with chronic Hepatitis B on Hepatocellular Carcinoma - a proof of concept study - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
STELLAR-002: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
IMbrave050: A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
AUSTRIA
WIEN
WIEN
The FAB-HCC Trial: Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
BELGICA
ANTWERPEN
EDEGEM (ANTWERPEN)
HepaVac-101: A phase I/II trial of IMA970A plus CV8102 following a single pre-vaccination infusion of cyclophosphamide in patients with very early, early and intermediate stage of hepatocellular carcinoma after any standard treatments - BE
Antwerp University Hospital - UZA
Dienst gastro-enterologie en hepatologie / Division of Gastroenterology and Hepatology
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma - BE
Institution: Information not provided - BE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation - BE
Hôpital Universitaire de Bruxelles (H.U.B) - Site Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BioPearl Microspheres Loaded With Doxorubicin to Treat Patients With Unresectable HCC: Prospective, Single Arm, Multi-centre Post-market Follow-up Study
Hôpital Universitaire de Bruxelles (H.U.B) - Site Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CheckMate 9DW: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma - BE
Hôpital Universitaire de Bruxelles (H.U.B) - Site Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation - BE
Hôpital Universitaire de Bruxelles (H.U.B) - Site Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PRECISION 2: Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination (HR) Genes, a Belgian Precision phase II basket study
Universitair Ziekenhuis Brussel
Oncologisch centrum
BELGICA
OOST-VLAANDEREN
GENT
TRACE Trial: Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of HCC: A Multicenter Randomized Controlled Trial- BE
Universitair ziekenhuis Gent (UZ Gent)
Radiologie
BELGICA
VLAAMS BRABANT
LEUVEN
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma - CA
Institution: Information not provided - CA
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma - CA
Institution: Information not provided - CA
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation-CA
Institution: Information not provided - CA
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma -CA
Institution: Information not provided - CA
ESPANHA
Cataluña
BARCELONA
The GOING Study: Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma progressing under sorafenib - ES
Hospital Clínic de Barcelona
Servicio de Hepatología
ESPANHA
Cataluña
BARCELONA
Phase I/II study on safety and efficacy of NMS-01940153E in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy -ES
Hospital Clínic de Barcelona
Servicio de Hepatología
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation (CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9DX) - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
COSMIC-312: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012) -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-937: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
EMERALD-1: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
SIERRA: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib (Rivoceranib) Mesylate Versus Sorafenib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
CheckMate 9DW: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma - ES
Institution: Information not provided - ES
ESPANHA
Navarra
PAMPLONA
NEOTOMA: Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial -ES
Clínica Universidad de Navarra
Unidad de Hepatología
ESTADOS UNIDOS
Arizona
SCOTTSDALE
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC) - US
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Institution: Information not provided - US
FRANCA
AUVERGNE-RHONE-ALPES
LYON
SOMAPROTECT01 : Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma by Laparotomy: Multicenter Randomized Double-blind Placebo Controlled Trial (Phase III)
CHU de Lyon HCL - GH Nord-Hôpital de la Croix Rousse
Service de chirurgie générale, digestive et transplantations hépatiques et intestinales
FRANCA
BOURGOGNE-FRANCHE-COMTE
BESANÇON
TERTIO : Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study -FR
CHU de Besançon - Hôpital Jean Minjoz
Service d'oncologie médicale
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
RESORCE: A randomized, double blind, placebo-controlled, multicenter phase III study of Regorafenib in patients with Hepatocellular Carcinoma after Sorafenib - FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis, Phase IIa Clinical Study
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma - FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE for patients with intermediate stage HCC - FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors -FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma -FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
MOIO: Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Metastatic Cancer in Response After 6 Months of Standard IO -FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Une première étude humaine de phase 1/2 avec escalade de dose des cellules T BOXR1030 chez des sujets atteints d'une tumeur solide avancée GPC3-Positive -FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
TRIPLET: Randomised, Open-label, Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy -FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
HOLMBRAVE : Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
SIERRA: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma - FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
LILLE
A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression - FR
CHRU de Lille - Hôpital Claude Huriez
Service des Maladies de l'appareil digestif et nutrition - Hépatologie
FRANCA
ILE-DE-FRANCE
CRÉTEIL
TACERTE : Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma (Phase II)
Hôpitaux Universitaires Henri Mondor
Service d'Hépatologie
FRANCA
NOUVELLE AQUITAINE
BORDEAUX
PRODIGE 21 : Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis - FR
CHU - Hôpitaux de Bordeaux
Direction de la Recherche Clinique et de l'Innovation (DRCI) - Hôpitaux de Bordeaux
IRLANDA
County Dublin
DUBLIN
TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE for patients with intermediate stage HCC - IE
St. Vincent's University Hospital
Department of Oncology
IRLANDA
County Dublin
DUBLIN
TACE-2 - A randomised placebo-controlled, double blinded, phase III trial of sorafenib in combination with transarterial chemoembolisation in hepatocellular cancer - IE
St. Vincent's University Hospital
Radiology Department
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
EVOLVE-1 : A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after failure of sorafenib treatment - IT
Institution: Information not provided - IT
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma - IT
Institution: Information not provided - IT
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma Progressing on or Intolerant to Prior Treatment With Immune Checkpoint Inhibitors: A Phase II Study (Immunocabo)
Institution: Information not provided - IT
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
Institution: Information not provided - IT
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma - IT
Institution: Information not provided - IT
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
SIERRA: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma - IT
Institution: Information not provided - IT
ITALIA
LOMBARDIA
MILANO
NEOTOMA: Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial - IT
Fondazione IRCCS Istituto Nazionale dei Tumori
S.C. Chirurgia Generale Indirizzo Oncologico 1 (Epato-gastro-pancreatico e Trapianto di Fegato)
ITALIA
LOMBARDIA
MILANO
Phase I/II study on safety and efficacy of NMS-01940153E in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy - IT
Fondazione IRCCS Istituto Nazionale dei Tumori
S.C. Oncologia Medica 1
JAPAO
JAPAN
ADDRESS : NOT PROVIDED - JP
EMERALD-1: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma - JP
Institution: Information not provided - JP
JAPAO
JAPAN
ADDRESS : NOT PROVIDED - JP
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors - JP
Institution: Information not provided - JP
JAPAO
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - JP
Institution: Information not provided - JP
REINO UNIDO
Greater London
LONDON
PRIME-HCC: Preliminary Assessment of Safety and Bioactivity of the Ipilimumab and Nivolumab Combination Prior to Liver Resection (LR) in Hepatocellular Carcinoma (HCC) GB
Imperial College NHS Trust
REINO UNIDO
Greater London
LONDON
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation-GB
King's College Hospital
King's College Hospital NHS Foundation Trust HQ
REINO UNIDO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma - GB
Institution: Information not provided - UK
SUECIA
Region Uppsala
UPPSALA
An open, single center two-step trial (A+B), comparing the safety and tolerability of idarubicin 10 mg and 15 mg after separate single hepatic intra-arterial injections of a drug formulation based on lipiodol emulsion in patients with unilobular or bilobular intermediate stage hepatocellular carcinoma. - SE
Uppsala Universitet
Department of Surgical Sciences
Ensaio (s) clínico (s) multinacional (ais)
REINO UNIDO
West Midlands
BIRMINGHAM
PHITT: Paediatric Hepatic International Tumour Trial
Birmingham Children's Hospital NHS Foundation Trust
Department of Oncology
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase I Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma, or Other Tumors Potentially Dependent on Hedgehog Signaling Pathway
Institution: Information not provided - CH
DINAMARCA
Fyn
ODENSE
Nordic-BTC-01: Neoadjuvant chemotherapy in patients with biliary tract carcinomas - A Nordic phase II study
Odense University hospital
Research Department of Clinical Oncology
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
DAREON(TM)-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas
Institution: Information not provided - US
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib versus Sorafenib plus Placebo as first line treatment for Hepatocellular Carcinoma (HCC) (coordination)
Institution: Information not provided - DE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-label first line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer
EORTC
European Organisation for the Research and Treatment of Cancer
CHINA
CHINA
ADDRESS: NOT PROVIDED - CN
FIRST-308: A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma.
Institution: Information not provided - CN
ESTADOS UNIDOS
Delaware
WILMINGTON
ESTADOS UNIDOS
Indiana
INDIANAPOLIS
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company World Headquarters
ESTADOS UNIDOS
New Jersey
RAHWAY
KEYNOTE 158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors
Merck, Sharp & Dohme Corp.
ESTADOS UNIDOS
Pennsylvania
PHILADELPHIA
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma (Coordination)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
KEYNOTE-240: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
TOPAZ-1: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
PROCLAIM-CX-2009: A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
CheckMate 74W: A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
FOENIX-CCA3: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)
Institution: Information not provided - US
SUECIA
Region Stockholm
ADDRESS: NOT PROVIDED - SE
A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations
Institution: Information not provided - SE
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
FIGHT-202: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
Institution: Information not provided - CH
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A First In Human, Open Label, Dose Escalation Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Clinical Activity Profile Of Single Agent RO7119929 (TLR7 Agonist) Administered Orally To Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Institution: Information not provided - CH
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
RESORCE: A randomized, double blind, placebo-controlled, multicenter phase III study of Regorafenib in patients with Hepatocellular Carcinoma after Sorafenib
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
YES-P: A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT) (Phase III)
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
SORAMIC: Evaluation of sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma
Institution: Information not provided - DE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
TRACE Trial: Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of HCC: A Multicenter Randomized Controlled Trial
Institution: Information not provided - BE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
Institution: Information not provided - BE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CheckMate 9DW: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma
Bristol Myers Squibb International Corporation
CANADA
Ontario
TORONTO
NEOTOMA: Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial.
Toronto General Hospital
University Health Network (UHN)
ESPANHA
Navarra
PAMPLONA
EMERALD-1: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma
Clínica Universidad de Navarra
ESTADOS UNIDOS
California
PLEASANTON
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Astex Pharmaceuticals, Inc
ESTADOS UNIDOS
Utah
SOUTH JORDAN
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Merit Medical Systems, Inc.
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
REACH: A multicenter, randomized, double-blind, phase 3 study of ramucirumab (imc-1121b) drug product and best supportive care (BSC) versus placebo and BSC as second-line treatment in patients with hepatocellular carcinoma following first-line therapy with sorafenib
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
METIV-HCC: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Randomized controlled phase II trial of ARQ 197 in patients with unresectable Hepatocellular Carcinoma (HCC) who have failed one prior systemic therapy
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Multicenter, Global, Randomized, Double-blind Study Of Axitinib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced Hepatocellular Carcinoma Following Failure Of One Prior Antiangiogenic Therapy
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma.
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
ARTISTRY-2: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma.
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
SIERRA: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma.
Institution: Information not provided - US
FRANCA
ILE-DE-FRANCE
RUEIL-MALMAISON
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study) (coordination)
Bristol Myers Squibb France
Bristol-Myers Squibb France
ISRAEL
ISRAEL
ADDRESS: NOT PROVIDED - IL
A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis
Institution: Information not provided - IL
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
HepaVac-101: A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments
Institution: Information not provided - IT
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Phase I/II Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy.
Institution: Information not provided - IT
PAISES BAIXOS
Utrecht
ADDRESS: NOT PROVIDED - NL
A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma
Institution: Information not provided - NL
REINO UNIDO
Greater London
ADDRESS: NOT PROVIDED - GB
TACE-2 - A randomised placebo-controlled, double blinded, phase III trial of sorafenib in combination with transarterial chemoembolisation in hepatocellular cancer
Institution: Information not provided - GB
REINO UNIDO
Greater London
SURREY
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumor.
The Royal Marsden
Royal Marsden NHS Foundation Trust
REINO UNIDO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE for patients with intermediate stage HCC
Institution: Information not provided - UK
SUECIA
Region Stockholm
ADDRESS: NOT PROVIDED - SE
HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Institution: Information not provided - SE
SUECIA
Region Stockholm
SÖDERTALJE
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH